These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 17198477)

  • 21. Non-alcoholic fatty liver disease.
    Smith BW; Adams LA
    Crit Rev Clin Lab Sci; 2011; 48(3):97-113. PubMed ID: 21875310
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CYP2E1 and oxidant stress in alcoholic and non-alcoholic fatty liver disease.
    Leung TM; Nieto N
    J Hepatol; 2013 Feb; 58(2):395-8. PubMed ID: 22940046
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of fatty liver, dietary fatty acid supplements, and obesity in the progression of alcoholic liver disease: introduction and summary of the symposium.
    Purohit V; Russo D; Coates PM
    Alcohol; 2004 Aug; 34(1):3-8. PubMed ID: 15670659
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The metabolic abnormalities associated with non-alcoholic fatty liver disease.
    Haque M; Sanyal AJ
    Best Pract Res Clin Gastroenterol; 2002 Oct; 16(5):709-31. PubMed ID: 12406441
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mitochondrial injury in steatohepatitis.
    Pessayre D; Fromenty B; Mansouri A
    Eur J Gastroenterol Hepatol; 2004 Nov; 16(11):1095-105. PubMed ID: 15489566
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PARP inhibition protects against alcoholic and non-alcoholic steatohepatitis.
    Mukhopadhyay P; Horváth B; Rajesh M; Varga ZV; Gariani K; Ryu D; Cao Z; Holovac E; Park O; Zhou Z; Xu MJ; Wang W; Godlewski G; Paloczi J; Nemeth BT; Persidsky Y; Liaudet L; Haskó G; Bai P; Boulares AH; Auwerx J; Gao B; Pacher P
    J Hepatol; 2017 Mar; 66(3):589-600. PubMed ID: 27984176
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Role of lipid peroxidation in non-alcoholic steatohepatitis].
    Fraenkel E; Lazúrová I; Fehér J
    Orv Hetil; 2004 Mar; 145(12):611-8. PubMed ID: 15119115
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Role of mitochondrial dysfunction in non-alcoholic steatohepatitis].
    Elloumi H; Arfaoui D; Nabli N; Ajmi S
    Tunis Med; 2003 Oct; 81(10):763-7. PubMed ID: 17722791
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Involvement of microsomal triglyceride transfer protein in nonalcoholic steatohepatitis in novel spontaneous mouse model.
    Shindo N; Fujisawa T; Sugimoto K; Nojima K; Oze-Fukai A; Yoshikawa Y; Wang X; Yasuda O; Ikegami H; Rakugi H
    J Hepatol; 2010 Jun; 52(6):903-12. PubMed ID: 20392512
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alterations of hepatic ATP homeostasis and respiratory chain during development of non-alcoholic steatohepatitis in a rodent model.
    Serviddio G; Bellanti F; Tamborra R; Rollo T; Romano AD; Giudetti AM; Capitanio N; Petrella A; Vendemiale G; Altomare E
    Eur J Clin Invest; 2008 Apr; 38(4):245-52. PubMed ID: 18339004
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serotonin mediates oxidative stress and mitochondrial toxicity in a murine model of nonalcoholic steatohepatitis.
    Nocito A; Dahm F; Jochum W; Jang JH; Georgiev P; Bader M; Renner EL; Clavien PA
    Gastroenterology; 2007 Aug; 133(2):608-18. PubMed ID: 17681180
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vitamin E alleviates non-alcoholic fatty liver disease in phosphatidylethanolamine N-methyltransferase deficient mice.
    Presa N; Clugston RD; Lingrell S; Kelly SE; Merrill AH; Jana S; Kassiri Z; Gómez-Muñoz A; Vance DE; Jacobs RL; van der Veen JN
    Biochim Biophys Acta Mol Basis Dis; 2019 Jan; 1865(1):14-25. PubMed ID: 30300671
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Regulation of synthesis and oxidation of fatty acids by adiponectin receptors (AdipoR1/R2) and insulin receptor substrate isoforms (IRS-1/-2) of the liver in a nonalcoholic steatohepatitis animal model.
    Matsunami T; Sato Y; Ariga S; Sato T; Shimomura T; Kashimura H; Hasegawa Y; Yukawa M
    Metabolism; 2011 Jun; 60(6):805-14. PubMed ID: 20846698
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nonalcoholic fatty liver disease.
    Krawczyk M; Bonfrate L; Portincasa P
    Best Pract Res Clin Gastroenterol; 2010 Oct; 24(5):695-708. PubMed ID: 20955971
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mitochondrial abnormality and oxidative stress in nonalcoholic steatohepatitis.
    Kojima H; Sakurai S; Uemura M; Fukui H; Morimoto H; Tamagawa Y
    Alcohol Clin Exp Res; 2007 Jan; 31(1 Suppl):S61-6. PubMed ID: 17331168
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug-induced toxicity on mitochondria and lipid metabolism: mechanistic diversity and deleterious consequences for the liver.
    Begriche K; Massart J; Robin MA; Borgne-Sanchez A; Fromenty B
    J Hepatol; 2011 Apr; 54(4):773-94. PubMed ID: 21145849
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Liver mitochondrial dysfunction and oxidative stress in the pathogenesis of experimental nonalcoholic fatty liver disease.
    Oliveira CP; Coelho AM; Barbeiro HV; Lima VM; Soriano F; Ribeiro C; Molan NA; Alves VA; Souza HP; Machado MC; Carrilho FJ
    Braz J Med Biol Res; 2006 Feb; 39(2):189-94. PubMed ID: 16470305
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel therapeutic targets for steatohepatitis.
    Sanyal AJ
    Clin Res Hepatol Gastroenterol; 2015 Sep; 39 Suppl 1():S46-50. PubMed ID: 26160474
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pediatric non-alcoholic fatty liver disease: Recent solutions, unresolved issues, and future research directions.
    Clemente MG; Mandato C; Poeta M; Vajro P
    World J Gastroenterol; 2016 Sep; 22(36):8078-93. PubMed ID: 27688650
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Review article: the pathogenesis of fibrosis in non-alcoholic steatohepatitis.
    Marra F; Aleffi S; Bertolani C; Petrai I; Vizzutti F
    Aliment Pharmacol Ther; 2005 Nov; 22 Suppl 2():44-7. PubMed ID: 16225472
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.